Subscribe To
KRTX / Karuna's (KRTX) Q3 Loss Wider-Than-Expected, Sales Miss
KRTX News
By Zacks Investment Research
November 3, 2023
Karuna's (KRTX) Q3 Loss Wider-Than-Expected, Sales Miss
Karuna's (KRTX) third-quarter 2023 earnings miss estimates. The company did not record any sales during the quarter. more_horizontal
By Seeking Alpha
October 16, 2023
Karuna Therapeutics: KarXT Could Become A New Standard Of Care In Schizophrenia
Karuna Therapeutics, Inc. stock had >8x gain after my Buy rating before successful Phase 3 trial data for KarXT in treating schizophrenia. The stock h more_horizontal
By Business Wire
October 4, 2023
Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 36th European College of Neuropsychopharmacology (ECNP) Congress
BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative more_horizontal
By Zacks Investment Research
September 29, 2023
Karuna (KRTX) Submits NDA Filing to FDA for Schizophrenia Drug
If approved, Karuna's (KRTX) KarXT will be the first new mechanism of action to treat schizophrenia in several decades. Data from three clinical studi more_horizontal
By Seeking Alpha
August 24, 2023
Karuna: NDA Filing Q3 Of 2023 And Expanded Potential With KarXT
Submission of New Drug Application of KarXT for the treatment of schizophrenia is expected in Q3, 2023. If FDA approval of KarXT is given for the trea more_horizontal
By Seeking Alpha
August 16, 2023
Karuna's Robust Liquidity Paves Way For KarXT Milestones (Rating Upgrade)
Karuna Therapeutics develops innovative treatments for psychiatric and neurological disorders, with their investigational drug KarXT targeting schizop more_horizontal
By Seeking Alpha
August 5, 2023
Karuna Therapeutics, Inc. (KRTX) Q2 2023 Earnings Call Transcript
Karuna Therapeutics, Inc. (NASDAQ:KRTX ) Q2 2023 Earnings Conference Call August 3, 2023 8:00 AM ET Company Participants Alexis Smith - Senior Directo more_horizontal
By Zacks Investment Research
August 4, 2023
Karuna (KRTX) Reports Narrower-Than-Expected Loss in Q2
Karuna (KRTX) reports mixed second-quarter 2023 results. The company beats estimates for earnings but misses the mark on sales. more_horizontal